THE FUTURE OF ORGAN TRANSPLANTATION: INNOVATIONS IN IMMUNOSUPPRESSION AND REJECTION PREVENTION

Organ transplantation continues to remain a vital component of treatment of end-stage organ failure, however, the issue of immunological rejection complicates the ability of a graft to survive the long term. This article examines the latest development in the field of immunosuppression, induction of tolerance, the use of biomarkers, and monitoring with the help of artificial intelligence (AI) through the lens of transplantation. We observe what extent biologics (such as monoclonal antibodies), small molecule based inhibitors (such as mTOR and JAK inhibitors) and pharmacogenomic- based tailored immunosuppressant regimens reduce the occurrence of acute and chronic rejection episodes. It was multi-tiered architecture and involved immunological tolerance approaches (regulatory T cells, gene editing) or profiling of molecular biomarkers (dd-cfDNA, cytokines) and machine learning-based diagnostic models. The nine synthetic datasets quantitatively analyzed demonstrated that the targeted therapy significantly extended graft survival (mean > 5.2 years), suppressed the instances of rejection (by >40% compared to regimes using standard doses), and maintained suitable levels of sufficient immunosuppressants in large (including those with bigger starting loads) patient groups. The visualization of 12 different kinds of visualization, including line, bar, scatter, and hybrid plots, indicated that the stability of biomarkers and the success rates predicted by AI kept improving over time. The stem cell therapies, combined with the gene-editing methods, made graft acceptability even stronger. It was also through the AI systems that early rejection was more easily detected and treatment plans were more efficiently optimised. These findings indicate the trend toward precision transplantation care, the combination of personalized immunomodulations and computer technologies that helps to prolong the graft lifetime, decrease side effects, and enhance patient outcomes. The potential to transform the future of long-term transplant treatment appears with the combination of regenerative biology and immunogenetics with AI as the science progresses proactively.